Cedra names two new directors

They join business development in generics and automation for the bioanalytical division

Cedra Corporation, a division of Worldwide Clinical Trials and provider of Phase I-IIb clinical research and bioanalytical services, has appointed John Pottier as senior director of business development in generics and Thomas Lloyd as director of automation for the Bioanalytical Group.

Pottier has more than 17 years within the sales and marketing sector of the contract research organisation (CRO) market.

Prior to joining Cedra, Pottier held positions with Novum Pharmaceutical Research Services and PRACS Institute/Cetero Research relating to business development.

Lloyd has more than 22 years of experience in developing and automating analytical and bioanalytical processes. His specific expertise is in automation systems and analytical instrument development, bioanalytical chemistry, in vitro DMPK studies, software programming and application, statistics, chemometrics and GLP requirements.

Prior to joining Cedra, Lloyd led the automation group at Pfizer, previously known as Wyeth Research. He has held previous positions at DuPont Merck Pharmaceutical Company and Glaxo.

You may also like

Research & Development
Bio-Rad expands precision oncology research portfolio for advanced molecular analysis workflows

Bio-Rad expands precision oncology research portfolio for advanced molecular analysis workflows

Expanded portfolio Includes new droplet digital PCR assays, Reagents and technologies to support oncology research applications and extend the capabilities of the QX700 ddPCR systems
Regulatory
Johnson & Johnson secures FDA approval for RYBREVANT FASPRO in head and neck cancer

Johnson & Johnson secures FDA approval for RYBREVANT FASPRO in head and neck cancer

The accelerated approval marks the first expansion of J&J's dual-targeted cancer therapy beyond lung cancer, with the subcutaneous treatment demonstrating a 42% response rate in a Phase Ib/II trial
Ingredients
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
You need to be a subscriber to read this article.
Click here to find out more.
Packaging
Embracing healthcare innovation with 2D codes

Embracing healthcare innovation with 2D codes

Pharmaceutical manufacturers already serialise medicines using 2D codes to meet regulatory requirements, but a 2D code can be so much more than a tick box for compliance, explains Ian Chapman, Strategic Manager for Digital Coding at Domino Printing Sciences
Manufacturing
Pace Life Sciences completes EMA GMP inspection at New Jersey CDMO facility

Pace Life Sciences completes EMA GMP inspection at New Jersey CDMO facility

The inspection supports renewal of the EU GMP certificate at the company's New Jersey site, which provides pharmaceutical analytical testing, microbiology and development services
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
UK Budget 2026: what it means for pharma manufacturing

UK Budget 2026: what it means for pharma manufacturing

VAT relief on free medicines, £1bn in new investment and revised capital allowances give pharma manufacturers progress — but gaps remain
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory
A completed reply is not a finalised case: how to test AI intake in pharma

A completed reply is not a finalised case: how to test AI intake in pharma

A medical information response marked complete says nothing about safety information that arrives later. Before accepting an AI intake demonstration, ask to see what happens to the next message: who assesses it, what stays pending and which dates are preserved
Subscribe now